Table 1 |
||||
|
Changes in clinical assessments, bone mineral density and laboratory analysis following anti-TNF treatment in AS patients |
||||
|
Baseline |
6 months |
12 months |
P |
|
|
|
||||
|
BASDAI |
5.11 ± 2.1 |
2.78 ± 2.4 |
2.78 ± 2.5 |
< 0.001 |
|
BASFI |
5.40 ± 2.7 |
2.96 ± 2.6 |
2.85 ± 2.7 |
< 0.001 |
|
BASMI |
4.06 ± 2.7 |
3.23 ± 2.6 |
3.07 ± 2.7 |
0.003 |
|
AsQoL, score |
10.03 ± 5.2 |
6.43 ± 6.4 |
6.40 ± 6.05 |
0.001 |
|
ESR, mm/hr |
23.75 ± 23.1 |
8.16 ± 15.6 |
7.3 ± 13.1 |
< 0.001 |
|
C-reactive protein, mg/dL |
37.03 ± 47.9 |
3.35 ± 4.1 |
7.21 ± 20.1 |
< 0.001 |
|
MMP-3, ng/mL |
48.6 ± 42.5 |
21.6 ± 22.5 |
23.3 ± 30.8 |
< 0.001 |
|
BMD lumbar spine, g/cm2 |
1.032 ± 0.175 |
1.049 ± 0.169 |
1.065 ± 0.169 |
< 0.001 |
|
BMD femoral neck, g/cm2 |
0.864 ± 0.160 |
0.865 ± 0.159 |
0.864 ± 0.161 |
0.051 |
|
BMD total femur, g/cm2 |
0.990 ± 0.165 |
0.986 ± 0.165 |
0.999 ± 0.171 |
0.981 |
|
Sclerostin, pmol/L |
60.5 ± 32.7 |
67.1 ± 31.9 |
72.7 ± 32.3 |
< 0.001 |
|
Sclerostin binding to LRP6, OD450 |
0.61 ± 0.13 |
ND |
0.60 ± 0.14 |
0.472 |
|
|
||||
|
Values are expressed as mean (SD). AS, ankylosing spondylitis; BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; BASMI, Bath AS Metrology Index; ASQoL, AS quality of life questionnaire; BMD, bone mineral density; ESR, erythrocyte sedimentation rate; MMP-3, matrix metalloproteinase 3; LRP6, low-density lipoprotein receptor-related protein 6; OD, optical density; ND, not done. |
||||
|
Saad et al. Arthritis Research & Therapy 2012 14:R216 doi:10.1186/ar4055 |
||||
